Austin-based Savara Pharmaceuticals has rounded up $11.4 million in cash to fuel the upstart biotech through a key transition phase: taking its lead development program through a crucial proof-of-concept study that could leave the biotech on the threshold of a late-stage trial.
Spectrum Pharmaceuticals snagged the rights to an orphan-designated, pivotal-stage cancer treatment coupled with a specialized delivery component that increases stability and solubility.
Researchers from around the country have found a way to deliver inflammation-reducing drugs to injured tissue using biodegradable nanoparticles.
Researchers in Japan have developed a way to release drugs via a gel that reacts to compression--in practice, the gel would allow patients to administer drugs "on demand" by way of hand pressure.
Amgen touted top-line results from a Phase III trial of an anti-cancer virus as a treatment for a deadly form of skin cancer, showing that talimogene laherparepvec met the primary goal for shrinking tumors in patients with late stages of the disease.
Alnylam began Phase I clinical trials for its RNAi-based treatment of TTR-mediated amyloidosis, or ATTR, a particularly menacing protein disorder that affects the nerves and the heart.
DC devices is developing the first technology that can treat diastolic heart failure without the need for invasive surgery, and the startup has snagged $10.7 million in venture financing.
Welcome to the "gamification" of life sciences research, where all you need is an Internet-connected device and a few minutes to play a part in advancing science. It's a growing trend within the open innovation and crowdsourcing movements sweeping the biopharma world. Check out the full report >>
In a first step toward developing a migraine diagnostic blood test, Johns Hopkins researchers are zeroing in on blood levels of a fat-derived protein as a potential biomarker
FDA Commissioner Margaret Hamburg had words of praise--wrapped in a not-so-subtle warning--when she addressed hundreds of biotech executives in Boston late last week.